My ePortfolio Register   

ESMO 2017 /
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.09.17
Views: 829
Rating:

Prof Kimberly Blackwell, Prof Hope Rugo, Prof Peter Schmid, Dr Mark Verrill

Professor Kimberley Blackwell (Duke University, North Carolina, USA) chairs an expert discussion on the latest in CDK inhibition in breast cancer and what this means for patients for ecancer at ESMO 2017 in Madrid.

Professor Blackwell is joined by Dr Mark Verrill (Freeman Hospital, Newcastle, UK), Professor Peter Schmid (St Bartholomew Hospital London, UK) and Professor Hope Rugo (University of California, San Francisco, USA).

The panel discuss CDK 4/6 inhibitors as a promising treatment option available for patients with metastatic HR /HER2- breast cancer, starting the discussion by looking at how ribociclib, abemaciclib, and palbociclib, are offering sustained long-term durable responses; in some cases, for more than two years, and with a manageable safety profile.

With recent data updates on the MONALEESA-2 trial at ASCO 2017, and anticipated data read outs for the MONARCH series at ESMO 2017, the panel debated the benefits of using CDK 4/6 as a 1st line therapeutic option in breast cancer patients, as no a sub-group of patients has yet been identified that will not benefit from using these agents. This then led onto the use of CDK 4/6 inhibitors being used in combination to achieve sustained PFS compared to a single agent, a favourable safety profile, and there being ‘no decrease’ in QoL when reviewing Patient Reported Outcomes (PROs).

Prof Blackwell and Dr Rugo gave their insights into the use of CDK 4/6 inhibitors within the United States, and due to the recent approval of ribociclib within the EU, Dr Verrill and Professor Schmid gave their perspectives on prescribing behaviours in the United Kingdom, which was further supplemented with discussions about patient access to drugs in the UK, looking at NICE, and the USA’s Assistance Programme.

The panel concluded that this is a very exciting time for clinicians as the presence of CDK 4/6 inhibitors has and will continue to make significant impacts within the field oncology, ensuring that patients are continuing to live a better quality of life, for longer.

Funded by Novartis Pharmaceuticals UK Ltd.
Novartis Pharmaceuticals UK Ltd. proposed the subject but had no input into the development of content. Editorial control remained with ecancer.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence